What is the recommended duloxetine dosage for adults, including initial dose, maximum dose, and adjustments for hepatic impairment, renal impairment, and elderly patients?

Duloxetine Dosage Recommendations

For most adult indications, start duloxetine at 30 mg once daily for one week, then increase to the target dose of 60 mg once daily, which is the recommended maintenance dose with no evidence that higher doses provide additional benefit. 1

Initial Dosing by Indication

Major Depressive Disorder (MDD)

• Standard approach: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or 30 mg twice daily) 1
• Alternative: Start at 30 mg once daily for 1 week to allow adjustment before increasing to 60 mg once daily 1
• Maximum dose: 120 mg/day has shown efficacy, but no evidence supports doses >60 mg/day conferring additional benefits 1

Generalized Anxiety Disorder (GAD)

• Adults <65 years: 60 mg once daily; may start at 30 mg once daily for 1 week 1
• Maximum: 120 mg/day studied, but doses >60 mg/day show no additional benefit 1

Diabetic Peripheral Neuropathic Pain (DPNP)

• Target dose: 60 mg once daily 1
• No evidence that doses >60 mg/day provide additional benefit, and higher doses are clearly less well tolerated 1
• For tolerability concerns: Consider lower starting dose 1

Fibromyalgia

• Start: 30 mg once daily for 1 week 1
• Target: 60 mg once daily 1
• No benefit from doses >60 mg/day, with higher rates of adverse reactions at increased doses 1

Chronic Musculoskeletal Pain

• Start: 30 mg once daily for 1 week 1
• Target: 60 mg once daily 1
• Higher doses: Not recommended—no additional benefit and increased adverse reactions 1

Special Population Adjustments

Elderly Patients (≥65 years)

For GAD in geriatric patients, initiate at 30 mg once daily for 2 weeks before considering increase to 60 mg/day. 1

• Start lower and titrate slower than younger adults 2
• In a study of elderly patients (median age 72 years) with MDD, duloxetine 60 mg once daily was safe and well tolerated with discontinuation rates similar to placebo (9.7% vs 8.7%) 3
• Consider that elderly patients are at greater risk for hyponatremia 1

Renal Impairment

Avoid duloxetine in patients with severe renal impairment (GFR <30 mL/min) or end-stage renal disease. 1

• Mild to moderate impairment (CrCl ≥30 mL/min): No dose adjustment necessary 4
• Severe impairment (CrCl <30 mL/min): Contraindicated—duloxetine exposure increases approximately 2-fold and metabolite exposure increases up to 9-fold 4
• DPNP patients: Since diabetes frequently complicates renal function, consider lower starting dose and gradual titration 1

Hepatic Impairment

Avoid duloxetine entirely in patients with chronic liver disease or cirrhosis. 1

• No dose adjustment recommendations exist because use is not recommended in any degree of hepatic impairment 1
• Duloxetine undergoes extensive hepatic metabolism via CYP1A2 and CYP2D6 5

Critical Dosing Considerations

Administration

• Swallow capsules whole—do not chew, crush, or open 1
• Can be taken with or without food 1
• The enteric coating protects duloxetine from premature degradation in acidic conditions 1

Titration Timeline

• Neuropathic pain guidelines: Allow 4 weeks at target dose for adequate trial 2
• MDD: 4-week adequate trial period 2
• Nausea (most common adverse effect) is reduced by starting at 30 mg once daily for 1 week before increasing to 60 mg 2

Drug Interactions Affecting Dose

• CYP1A2 inhibitors (e.g., fluvoxamine): Increase duloxetine exposure by 460%—avoid combination 5
• Smoking: Decreases duloxetine concentration by 30% 5
• CYP2D6 inhibitors: Increase exposure to lesser extent; no dose adjustment needed 5

Discontinuation

• Taper gradually rather than abrupt cessation to minimize withdrawal symptoms (dizziness, headache, nausea, paresthesia, irritability) 1
• Allow at least 5 days after stopping duloxetine before starting an MAOI 1

Common Pitfalls to Avoid

1. Do not exceed 60 mg/day routinely—the FDA label is clear that higher doses show no additional efficacy across most indications while increasing adverse effects 1

2. Do not use in severe renal impairment—metabolite accumulation occurs even though parent drug clearance appears preserved 4

3. Screen for hepatic disease before initiating—duloxetine is contraindicated in cirrhosis 1

4. Monitor blood pressure—though clinically significant changes are uncommon, orthostatic hypotension can occur, particularly in elderly patients 3

5. Start low in elderly patients—use 30 mg once daily for 2 weeks in geriatric GAD patients before advancing 1